According to 2022 NCCN Clinical Practice Guidelines, the first-generation TKI, imatinib, is a preferred first-line agent for low-risk patients in the chronic phase of CML. Other preferred agents include the second-generation TKIs bosutinib, dasatinib, or nilotinib. A clinical trial may also be considered.
Learn more about the management of CML.
Medscape © 2022 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Emmanuel C. Besa. Fast Five Quiz: Chronic Myelogenous Leukemia Management - Medscape - Sep 21, 2022.